Trabectome alternative for glaucoma surgery

Article

Trabectome, a device that ablates the arc of trabecular meshwork, is a safe and effective alternative to glaucoma surgery, according to a recent paper.

Trabectome, a device that ablates the arc of trabecular meshwork, is a safe and effective alternative to glaucoma surgery, according to a recent paper.

The investigation, led by Dr M. Maeda, Department of Ophthalmology, Gifu Red Cross Hospital, Gifu Social Insurance Chukyo Hospital, Nagoya, Japan, involved performing Trabectome surgeries on 80 eyes of 69 adult Japanese patients with or without previous surgery or laser treatment.

The team measured Goldmann applanation intraocular pressure (IOP), adjunctive medications, corneal endothelial cell density and best corrected visual acuity (BCVA). Intraoperative and postoperative adverse events were also recorded.

Mean preoperative IOP was 26.6±8.1 mmHg and decreased to a mean IOP of 17.4±3.4 mmHg six months after surgery. There were no complications such as choroidal effusion, choroidal haemorrhage or infection occurred.

Of the patients studied, 16.3% required surgical intervention and one case underwent cataract extraction during the follow-up period. There was an overall decrease of approximately 30% in IOP six months postoperatively.

The abstract can be viewed in the latest issue of the Journal of Glaucoma.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.